ATE230795T1 - In situ modifikation und manipulation von stammzellen des zentralen nervensystems - Google Patents

In situ modifikation und manipulation von stammzellen des zentralen nervensystems

Info

Publication number
ATE230795T1
ATE230795T1 AT94931482T AT94931482T ATE230795T1 AT E230795 T1 ATE230795 T1 AT E230795T1 AT 94931482 T AT94931482 T AT 94931482T AT 94931482 T AT94931482 T AT 94931482T AT E230795 T1 ATE230795 T1 AT E230795T1
Authority
AT
Austria
Prior art keywords
cells
situ
stem cells
manipulation
nervous system
Prior art date
Application number
AT94931482T
Other languages
English (en)
Inventor
Samuel Weiss
Brent A Reynolds
Der Kooy Derek Van
Cindi Morshead
Constance Craig
Original Assignee
Neurospheres Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurospheres Holdings Ltd filed Critical Neurospheres Holdings Ltd
Application granted granted Critical
Publication of ATE230795T1 publication Critical patent/ATE230795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
AT94931482T 1993-11-09 1994-11-08 In situ modifikation und manipulation von stammzellen des zentralen nervensystems ATE230795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14950893A 1993-11-09 1993-11-09
PCT/CA1994/000614 WO1995013364A1 (en) 1993-11-09 1994-11-08 In situ modification and manipulation of stem cells of the central nervous system

Publications (1)

Publication Number Publication Date
ATE230795T1 true ATE230795T1 (de) 2003-01-15

Family

ID=22530608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931482T ATE230795T1 (de) 1993-11-09 1994-11-08 In situ modifikation und manipulation von stammzellen des zentralen nervensystems

Country Status (12)

Country Link
EP (1) EP0728194B1 (de)
JP (1) JP3952508B2 (de)
CN (1) CN1141058A (de)
AT (1) ATE230795T1 (de)
AU (1) AU697894B2 (de)
CA (1) CA2175992C (de)
DE (1) DE69431993T2 (de)
DK (1) DK0728194T3 (de)
ES (1) ES2189807T3 (de)
FI (1) FI120455B (de)
NO (1) NO317724B1 (de)
WO (1) WO1995013364A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI971956L (fi) * 1994-11-14 1997-07-04 Neurospheres Holdings Ltd Hermosolujen lisääntymisen säännöstely
WO1997035605A1 (en) * 1996-03-26 1997-10-02 Neurospheres Holdings Ltd. Manipulation of mitotically active cells of the hippocampal region of the brain
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US6787355B1 (en) 1996-08-26 2004-09-07 Mcgill University Multipotent neural stem cells from peripheral tissues and uses thereof
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
CA2216439A1 (en) * 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
WO1998022127A1 (en) * 1996-11-15 1998-05-28 Neurospheres Holdings Ltd. Pretreatment with growth factors to protect against cns damage
US20020123143A1 (en) 1997-08-22 2002-09-05 Jean Toma Multipotent stem cells from peripheral tissues and uses thereof
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
SE9802264D0 (sv) 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
US6541247B1 (en) 1998-06-25 2003-04-01 Neuronova Ab Method of isolating ependymal neural stem cells
US7544509B2 (en) 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
AU3499801A (en) 2000-02-11 2001-08-20 Schepens Eye Res Inst Isolation and transplantation of retinal stem cells
WO2002069975A1 (en) * 2001-03-02 2002-09-12 Stem Cell Therapeutics Inc. Use of estrogen to induce neural stem cell increase
AU2002325712C1 (en) 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
JP4906231B2 (ja) 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
EP1471970A4 (de) 2002-01-14 2006-08-02 Univ Illinois Neue multipotente säugetier-stammzellen und zusammensetzungen, verfahren zur herstellung und verfahren zu ihrer verabreichung
AU2003250697B2 (en) * 2002-07-30 2008-05-01 Stem Cell Therapeutics Inc. Oligodendrocyte production from multipotent neural stem cells
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
WO2005077404A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
CN101084303A (zh) 2004-11-17 2007-12-05 神经干公司 用于治疗神经变性症状的人类神经细胞的移植
US7534765B2 (en) 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
KR20080103108A (ko) 2006-03-17 2008-11-26 스템 셀 테라퓨틱스 코포레이션 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
JPWO2008093827A1 (ja) * 2007-02-01 2010-05-20 財団法人大阪産業振興機構 中枢神経障害治療剤及び中枢神経障害の治療方法
JP2009278873A (ja) * 2008-05-19 2009-12-03 Japan Health Science Foundation 培地および培養方法
CN103237553A (zh) 2010-07-28 2013-08-07 神经干细胞公司 治疗和/或逆转神经退行性疾病和/或病症的方法
CN108588025A (zh) 2012-02-17 2018-09-28 斯格本斯眼科研究所 人视网膜祖细胞的表型谱
WO2014157047A1 (ja) * 2013-03-27 2014-10-02 千葉県 神経変性疾患治療剤
MX382488B (es) 2014-10-20 2025-03-13 Neuralstem Inc Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
WO2016063985A1 (ja) 2014-10-24 2016-04-28 大日本住友製薬株式会社 神経組織の製造方法
SG11201809201UA (en) * 2016-04-22 2018-11-29 Sumitomo Dainippon Pharma Co Ltd Method for producing retinal tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
ATE262912T1 (de) * 1993-01-29 2004-04-15 Neurospheres Holdings Ltd Genetische modifikation von neuralen stammzellen

Also Published As

Publication number Publication date
DE69431993T2 (de) 2003-11-27
DE69431993D1 (de) 2003-02-13
DK0728194T3 (da) 2003-04-22
EP0728194B1 (de) 2003-01-08
JPH09507747A (ja) 1997-08-12
AU697894B2 (en) 1998-10-22
ES2189807T3 (es) 2003-07-16
WO1995013364A1 (en) 1995-05-18
FI961855L (fi) 1996-06-04
CN1141058A (zh) 1997-01-22
AU8056194A (en) 1995-05-29
JP3952508B2 (ja) 2007-08-01
EP0728194A1 (de) 1996-08-28
NO317724B1 (no) 2004-12-13
CA2175992C (en) 2008-04-01
FI961855A0 (fi) 1996-04-30
NO961859L (no) 1996-07-03
FI120455B (fi) 2009-10-30
CA2175992A1 (en) 1995-05-18
NO961859D0 (no) 1996-05-08

Similar Documents

Publication Publication Date Title
DE69431993D1 (de) In situ modifikation und manipulation von stammzellen des zentralen nervensystems
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
MY125594A (en) Immortalized cell lines for virus growth
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DK0395355T3 (da) Frigivelse af celler fra affinitetsmatricer
GB9308271D0 (en) Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE60120151D1 (de) Isolierung von mesenchymalen stammzellen und deren verwendung
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
EP0892849A4 (de) Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen
WO2000066730A3 (en) Laminin 2 and methods for its use
ATE345496T1 (de) In-vitro-musters für zns - funktion und dysfunktion
ATE473273T1 (de) Angereicherte zellpopulationen des zentralen nervensystems
ATE231727T1 (de) Zusammensetzung für verbesserung der pankreasfunktion
DE69504646D1 (de) Herstellung und stabilisierung von zellsuspensionen
DE3572368D1 (en) Microorganisms of the strain phanerochaete chrysosporium and their use
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
EP0244361A3 (en) Individual beta-form crystals of tetrakis-û3-(3,5-di-t-butyl-4-hydroxyphenyl)-propionyloxymethyl¨ methane and process for their manufacture
Pintér et al. Calpeptin, a calpain inhibitor, promotes neurite elongation in differentiating PC12 cells
GB1292701A (en) Improvements in or relating to the thermal hydrodealkylation of alkylbenzene compounds
DE69737101D1 (de) Zusammensetzungen zur gentransfer in das zentrale nervensystem
IS5613A (is) Notkun CD137 til að stuðla að fjölgun jaðar-einkjörnunga
DK1007647T3 (da) Höjniveauekspression af INGAP
MY105082A (en) Separation process

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0728194

Country of ref document: EP